What's Happening?
Phanes Therapeutics, a clinical-stage biotech company, has announced updated positive results from its Phase 2 clinical trial of spevatamig (PT886) in combination with chemotherapy for the treatment of metastatic pancreatic ductal adenocarcinoma (PDAC).
The results were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Spevatamig, an anti-CLDN18.2/CD47 bispecific antibody, showed potential as an effective first-line treatment for patients with metastatic PDAC. The trial demonstrated that the combination of spevatamig with chemotherapy was well tolerated and showed promising efficacy, with a 52.4% overall response rate and a 90.5% disease control rate. The median progression-free survival was 7.3 months, and the median overall survival was 14.7 months in U.S. patients. Phanes plans to advance spevatamig to a Phase 3 registrational study.
Why It's Important?
The development of spevatamig represents a significant advancement in the treatment of metastatic pancreatic cancer, a disease known for its poor prognosis and limited treatment options. The promising results from the Phase 2 trial suggest that spevatamig could offer a new therapeutic option for patients with this aggressive cancer. The potential for spevatamig to be used as a first-line treatment could improve survival rates and quality of life for patients. Additionally, the drug's mechanism as an innate immunity enhancer offers a novel approach to cancer treatment, particularly for tumors that do not respond well to existing immunotherapies.
What's Next?
Phanes Therapeutics is preparing to move spevatamig into a Phase 3 trial, which will further evaluate its efficacy and safety in a larger patient population. The company is also exploring the use of spevatamig in other cancer indications. The success of the upcoming trials could lead to regulatory approval and commercialization, providing a new treatment option for patients with metastatic pancreatic cancer. The biotech industry and oncology community will be closely monitoring the progress of these trials.
